Calibrate Reviews Tirzepatide
Treated interchangeably with semaglutide as a first-line choice, selected on tolerability and coverage rather than on a cost hierarchy. The quarterly physician cadence carries across.
Sold as Zepbound, Mounjaro · Reviewed September 19, 2026
What “First-line” means here
Prescribed as a first-line option. No lower-cost trial is required before a member can start.
The pairing
How Calibrate handles Tirzepatide
These are the vendor-specific mechanics that determine what this molecule actually costs you and whether members stay on it long enough to benefit.
- Access status
- First-line
- Gating
- Same eligibility as semaglutide. No step therapy.
- Prescribes directly
- Yes
- Step therapy
- No
- Prior authorization
- Yes
- Titration protocol
- Physician-directed titration with mandatory quarterly video visits and lab monitoring
- Off-ramp
- One-year maintenance curriculum after target weight, coach-led
- Care team
- Board-certified physicians, Nurse practitioners, Accountability coaches
Ask Calibrate this
When a member is eligible for both, what actually determines whether they start tirzepatide instead of semaglutide — and does prescriber compensation vary between them?
Watch out
The weight-loss guarantee excludes pharmacy spend entirely. It protects the program fee, not your budget.
The molecule
Tirzepatide in one page
The dual-incretin agent producing the largest average weight reductions recorded in this class. Higher efficacy, comparable cost, and rapidly growing share of employer spend.
Clinical profile
- Drug class
- Dual GIP/GLP-1 receptor agonist
- Brand names
- Zepbound — Chronic weight managementMounjaro — Type 2 diabetes
- Mechanism
- Agonizes both GIP and GLP-1 receptors. The dual mechanism is the accepted explanation for its efficacy advantage over single-agonist GLP-1s, though the relative contribution of GIP remains debated.
- Administration
- Once-weekly subcutaneous injection.
- Titration
- Initiated at a low weekly dose with escalation approximately every four weeks. The full ladder to the highest maintenance dose runs longer than semaglutide's, extending the window in which members are on drug but not yet at target.
- Typical result
- In registrational trials, average body-weight reduction of roughly a fifth of starting weight at about 72 weeks at higher doses — the highest reported in this class. Real-world persistence gaps apply here as they do everywhere.
- Generic available
- No
Known side effects
- Gastrointestinal effects broadly similar to other incretin agents, again concentrated in escalation
- Gallbladder events and pancreatitis reported at low rates
- Class boxed warning regarding thyroid C-cell tumors observed in rodents
- Lean-mass loss proportional to the larger total reduction, which matters more at this efficacy level
What benefits teams need to know
Higher efficacy is not automatically better economics
Greater average reduction at similar unit cost improves cost per point of weight lost. It also increases the likelihood members stay on therapy longer, which raises total spend. Model both effects; vendors will only show you the first.
Longer titration extends your exposure
A longer escalation ladder means more months of spend before a member reaches maintenance. If your program has a continuation-review gate, make sure the review point is set against this molecule's actual timeline rather than semaglutide's.
Lean mass deserves more attention here
Larger total weight reduction means larger absolute lean-mass loss. Vendors with real protein and resistance-training protocols matter more on this molecule than on lower-efficacy agents, particularly in older populations.
Alternatives
Other vendors and Tirzepatide
Same molecule, materially different access rules. The status column is where the cost difference lives.
| Vendor | Access | Score | PMPM |
|---|---|---|---|
| Virta Health Metabolic specialist | Escalation only | 8.7 | $40–$95 |
| Omada Health Coaching companion | Companion support | 8.4 | $32–$58 |
| Form Health Full-service clinical | First-line | 8.0 | $58–$105 |
| Twin Health Metabolic specialist | Escalation only | 7.8 | $55–$120 |
| Found Full-service clinical | Escalation only | 7.6 | $45–$85 |
| Vida Health Full-service clinical | Escalation only | 7.5 | $38–$78 |
Same vendor
Calibrate across the formulary
How this vendor positions each molecule tells you more about its cost discipline than any single review does.
A first-line option with no required lower-cost trial. Physician-directed titration with quarterly video visits and lab monitoring is genuinely above the market norm for clinical intensity.
Available but rarely the starting point. In practice it appears where the weekly agents are contraindicated or unavailable rather than as a deliberate cost step.
Used alongside incretin therapy for members with glycemic indications rather than as a standalone weight intervention or a required first rung.